Keros Therapeutics, Inc. (KROS) — SEC Filings
Keros Therapeutics, Inc. (KROS) — 50 SEC filings. Latest: 4 (Apr 17, 2026). Includes 37 8-K, 5 10-Q, 3 DEFA14A.
View Keros Therapeutics, Inc. on SEC EDGAR
Overview
Keros Therapeutics, Inc. (KROS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Keros Therapeutics, Inc. reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $110.475 million, a stark contrast to the net loss of $141.327 million in the same period of 2024. This was primarily driven by a substantial increase in total
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 48 neutral, 1 mixed. The dominant filing sentiment for Keros Therapeutics, Inc. is neutral.
Filing Type Overview
Keros Therapeutics, Inc. (KROS) has filed 1 4, 1 144, 5 10-Q, 37 8-K, 3 DEFA14A, 2 DEF 14A, 1 10-K with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of KROS's 46 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 29 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $243,676,000 |
| Net Income | $110,475,000 |
| EPS | N/A |
| Debt-to-Equity | 0.06 |
| Cash Position | $693,472,000 |
| Operating Margin | 39.7% |
| Total Assets | $742,783,000 |
| Total Debt | $39,203,000 |
Key Executives
- Mary
- David
- Dr. Michael R. Rickert
- Dr. Sarah L. Hough
- Mr. David M. E. Smith
- Dr. Michael R. Rick
- Dr. Jessica L. Smith
Industry Context
Keros Therapeutics operates in the highly competitive biotechnology sector, focusing on developing treatments for rare diseases and other serious conditions. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Success often hinges on innovation, strategic partnerships, and the ability to navigate complex clinical trials and approval processes.
Top Tags
8-K (13) · regulatory-filing (10) · sec-filing (8) · corporate-filing (6) · corporate-governance (5) · 8-k (5) · filing (5) · financials (4) · proxy-statement (4) · regulatory (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $110.475M | For the nine months ended September 30, 2025, a significant turnaround from a $141.327M net loss in 2024. |
| Total Revenue | $243.676M | For the nine months ended September 30, 2025, a substantial increase from $508K in 2024, primarily from license revenue. |
| License Revenue | $205.355M | Key driver of revenue growth for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $693.472M | As of September 30, 2025, indicating strong liquidity. |
| Capital Return | $375.0M | Amount of excess capital the Board plans to return to stockholders. |
| Net Loss | $7.280M | For the three months ended September 30, 2025, showing quarterly volatility despite year-to-date profit. |
| Total Operating Expenses | $146.837M | For the nine months ended September 30, 2025, a decrease from $158.087M in 2024. |
| Outstanding Shares | 40,632,164 | As of September 30, 2025, relevant for per-share metrics. |
| Net Loss (Q2 2025) | $45.2M | Increased from $35.1M in Q2 2024, indicating higher R&D spend. |
| Net Loss (YTD Q2 2025) | $88.7M | Widened from $68.2M in YTD Q2 2024, reflecting ongoing pipeline investment. |
| Cash & Equivalents (June 30, 2025) | $350.5M | Slight decrease from $380.1M at year-end 2024, but still a strong runway. |
| Revenue (Q2 2025) | 0 | Consistent with prior periods, as expected for a clinical-stage biotech. |
| SEC File Number | 001-39264 | Identifies Keros Therapeutics' filings with the SEC. |
| EIN | 81-1173868 | Employer Identification Number for Keros Therapeutics. |
| IRS Employer Identification No. | 81-1173868 | Tax identification number for the company. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Keros Therapeutics, Inc. (KROS)?
Keros Therapeutics, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 37 8-K, 5 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KROS filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Keros Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Keros Therapeutics, Inc. (KROS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Keros Therapeutics, Inc.?
Key financial highlights from Keros Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KROS?
The investment thesis for KROS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Keros Therapeutics, Inc.?
Key executives identified across Keros Therapeutics, Inc.'s filings include Mary, David, Dr. Michael R. Rickert, Dr. Sarah L. Hough, Mr. David M. E. Smith and 2 others.
What are the main risk factors for Keros Therapeutics, Inc. stock?
Of KROS's 46 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 29 low-risk.
What are recent predictions and forward guidance from Keros Therapeutics, Inc.?
Forward guidance and predictions for Keros Therapeutics, Inc. are extracted from SEC filings as they are enriched.